BRAF and neoplasm: Where genetic services were available, pedigree analysis was offered in ten countries, genetic counselling in eight countries, IHC or MSI-analysis in eight countries, MLH1-promotor methylation or BRAF-analysis of tumours (performed to exclude methylation of the MLH1-promotor as cause of loss of MMR-function) in eight countries and (Sanger) sequencing or Next Generation Sequencing (NGS) in ten countries.